Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Tokyo Government To Stock Up Flu Drugs For 4 Million People

This article was originally published in PharmAsia News

Executive Summary

To better prepare for a flu pandemic, the Tokyo government has proposed a ¥9 billion budget to supply Tamiflu and Relenza for 3 to 4 million people. It is estimated that 3.8 million in Tokyo could be infected in a global avian flu pandemic. However, the Ministry of Health, Labor and Welfare only provides Tokyo Tamiflu for 1.02 million and Relenza for 20,000. Considering MHLW's supply to be insufficient, Tokyo Governor Shintaro Ishihara pushed for the additional budget. According to the MHLW, the national flu drug stocks pile is prepared for 28 million people, and Tokyo is the first local government to stock up on the flu drugs. (Click here for more - Japanese language)

You may also be interested in...

Finance Watch: Biopharma VC Explosion Extends To Tools, Services

Private Company Edition: Venture capital financings didn’t take a break during Thanksgiving week. In addition to the $800m Resilience raised to fund manufacturing services, SomaLogic closed a $121m series A round to fund its proteomic tools for drug discovery and diagnostics development.

Zimmer Biomet Buys Sternal Closure Company A&E Medical

The $250m deal adds A&E Medical’s sternal sutures, cable systems, and rigid fixation systems to Zimmer Biomet’s Dental, Spine & Craniomaxillofacial and Thoracic business.

Ovid Shifts Focus After Angelman Syndrome Drug Disappoints In Phase III

The Phase III clinical trial showed a noticeable placebo effect compared with OV101.




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts